NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of “Moderate Buy” from Brokerages

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has earned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $38.25.

NRXP has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Friday, May 8th. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of NRx Pharmaceuticals in a research note on Monday, April 27th. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. Ascendiant Capital Markets increased their price objective on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th.

NRx Pharmaceuticals Trading Down 2.1%

Shares of NRXP opened at $4.18 on Tuesday. The firm has a fifty day simple moving average of $3.87 and a two-hundred day simple moving average of $2.80. The firm has a market cap of $151.44 million, a PE ratio of -3.83 and a beta of 2.19. NRx Pharmaceuticals has a 1-year low of $1.62 and a 1-year high of $5.05.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $19.43 million. As a group, research analysts forecast that NRx Pharmaceuticals will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NRXP. Anson Funds Management LP boosted its stake in shares of NRx Pharmaceuticals by 50.3% during the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock worth $8,249,000 after acquiring an additional 1,018,853 shares during the last quarter. Vanguard Group Inc. grew its position in shares of NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after acquiring an additional 82,781 shares during the period. AdvisorShares Investments LLC increased its stake in shares of NRx Pharmaceuticals by 28.2% in the 1st quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock worth $896,000 after purchasing an additional 92,463 shares in the last quarter. Commonwealth Equity Services LLC purchased a new stake in shares of NRx Pharmaceuticals in the 4th quarter worth $994,000. Finally, Geode Capital Management LLC raised its holdings in NRx Pharmaceuticals by 17.8% in the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock worth $593,000 after purchasing an additional 33,004 shares during the period. 4.27% of the stock is currently owned by institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.